Nuveen Asset Management LLC Has $8.21 Million Stock Holdings in Bioventus Inc. (NYSE:BVS)

Nuveen Asset Management LLC boosted its holdings in Bioventus Inc. (NYSE:BVS - Free Report) by 20.9% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 782,137 shares of the company's stock after purchasing an additional 135,236 shares during the period. Nuveen Asset Management LLC owned about 0.96% of Bioventus worth $8,212,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in BVS. Vanguard Group Inc. grew its position in Bioventus by 18.7% in the fourth quarter. Vanguard Group Inc. now owns 2,462,081 shares of the company's stock valued at $25,852,000 after purchasing an additional 388,174 shares in the last quarter. Driehaus Capital Management LLC grew its position in Bioventus by 33.7% in the fourth quarter. Driehaus Capital Management LLC now owns 1,119,855 shares of the company's stock valued at $11,758,000 after purchasing an additional 282,341 shares in the last quarter. American Century Companies Inc. lifted its stake in Bioventus by 38.7% in the fourth quarter. American Century Companies Inc. now owns 884,673 shares of the company's stock valued at $9,289,000 after acquiring an additional 246,645 shares during the last quarter. BNP Paribas Financial Markets acquired a new stake in Bioventus in the fourth quarter valued at $1,659,000. Finally, Dimensional Fund Advisors LP lifted its stake in Bioventus by 55.4% in the fourth quarter. Dimensional Fund Advisors LP now owns 427,422 shares of the company's stock valued at $4,488,000 after acquiring an additional 152,311 shares during the last quarter. Institutional investors own 62.94% of the company's stock.

Bioventus Stock Performance

BVS stock traded down $0.04 during trading hours on Monday, reaching $6.44. The stock had a trading volume of 410,547 shares, compared to its average volume of 454,841. The stock has a market capitalization of $529.01 million, a PE ratio of -10.56 and a beta of 0.95. The company has a debt-to-equity ratio of 1.85, a current ratio of 1.41 and a quick ratio of 0.99. The stock has a 50-day simple moving average of $7.42 and a 200 day simple moving average of $9.41. Bioventus Inc. has a fifty-two week low of $5.28 and a fifty-two week high of $14.38.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on BVS. Canaccord Genuity Group reiterated a "buy" rating and issued a $15.00 price target on shares of Bioventus in a research note on Monday, March 17th. Craig Hallum set a $15.00 price target on shares of Bioventus and gave the company a "buy" rating in a research note on Wednesday, May 7th.

Insider Transactions at Bioventus

In other news, CFO Mark Leonard Singleton sold 3,875 shares of the firm's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total transaction of $29,333.75. Following the completion of the sale, the chief financial officer now owns 141,088 shares in the company, valued at approximately $1,068,036.16. This trade represents a 2.67% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. In the last 90 days, insiders sold 13,330 shares of company stock worth $115,291. 32.90% of the stock is owned by insiders.

Bioventus Company Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.